Research Square (Research Square),
Journal Year:
2024,
Volume and Issue:
unknown
Published: Dec. 25, 2024
Abstract
Aim
Serum
mac-2-binding
protein
glycosylation
isomer
(M2BPGi)
is
a
new
biomarker
for
liver
fibrosis.
However,
its
performance
in
metabolic
dysfunction-associated
steatotic
disease
(MASLD),
particularly
obese
patients,
remains
to
be
explored.
Methods
This
study
evaluated
the
role
of
M2BPGi
predicting
fibrosis
205
patients
with
MASLD
using
magnetic
resonance
elastography
(MRE)
as
reference.
The
was
compared
vibration-controlled
transient
(VCTE),
FIB-4,
APRI,
and
NFS.
PNPLA3,
TM6SF2,
HSD17B13
polymorphisms
were
assessed
by
allelic
discrimination
assays.
Results
area
under
ROC
curves
VCTE,
NFS
differentiating
significant
0.95
(95%
CI;
0.91–0.98),
0.85
(0.79–0.92),
0.81
(0.74–0.89),
0.79
(0.71–0.87)
0.80
(0.72–0.87)
(all
P
<
0.001),
respectively.
optimal
cut-off
values
fibrosis,
advanced
cirrhosis
0.82,
0.95,
1.23
index
(COI),
yielding
satisfactory
sensitivity,
specificity,
diagnostic
accuracy.
consistent
among
subgroups
according
BMI,
while
AUROCs
remarkably
declined
BMI
≥
30
kg/m2.
Patients
PNPLA3
GG
genotype
had
significantly
higher
than
those
CC/CG
genotypes.
In
multivariate
analysis,
independent
factors
associated
M2BPGi,
rs738409.
Conclusion
Our
data
demonstrated
that
serum
accurately
across
different
indicating
this
could
apply
non-obese
clinical
settings.
Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(2), P. 415 - 415
Published: Feb. 9, 2025
Background:
Serum
mac-2-binding
protein
glycosylation
isomer
(M2BPGi)
is
a
new
biomarker
for
liver
fibrosis.
However,
its
performance
in
metabolic
dysfunction-associated
steatotic
disease
(MASLD),
particularly
obese
patients,
remains
to
be
explored.
Methods:
This
study
evaluated
the
role
of
M2BPGi
predicting
fibrosis
205
patients
with
MASLD
using
magnetic
resonance
elastography
(MRE)
as
reference.
The
was
compared
vibration-controlled
transient
(VCTE),
FIB-4,
APRI,
and
NFS.
PNPLA3,
TM6SF2,
HSD17B13
polymorphisms
were
assessed
by
allelic
discrimination
assays.
Results:
area
under
ROC
curves
VCTE,
NFS
differentiating
significant
0.95
(95%
CI;
0.91-0.98),
0.85
(0.79-0.92),
0.81
(0.74-0.89),
0.79
(0.71-0.87),
0.80
(0.72-0.87)
(all
p
<
0.001),
respectively.
optimal
cut-off
values
fibrosis,
advanced
cirrhosis
0.82,
0.95,
1.23
index
(COI);
yielding
satisfactory
sensitivity,
specificity,
diagnostic
accuracy.
consistent
among
subgroups
according
BMI,
while
AUROCs
remarkably
decreased
BMI
≥
30
kg/m2.
Patients
PNPLA3
GG
genotype
had
significantly
higher
than
those
CC/CG
genotypes.
In
multivariate
analysis,
independent
factors
associated
M2BPGi,
rs738409.
Conclusions:
Our
data
demonstrated
that
serum
accurately
across
different
indicating
this
could
apply
non-obese
clinical
settings.
JGH Open,
Journal Year:
2025,
Volume and Issue:
9(4)
Published: April 1, 2025
Noninvasive
tests
(NITs),
such
as
platelet-based
indices
and
ultrasound/MRI
elastography,
are
widely
used
to
assess
liver
fibrosis
in
metabolic
dysfunction-associated
steatotic
disease
(MASLD).
However,
platelet
counts
not
routinely
included
Japanese
health
check-ups,
limiting
their
utility
large-scale
screenings.
Additionally,
while
effective,
is
costly
less
accessible
routine
practice.
Most
existing
AI-based
models
incorporate
these
markers,
restricting
applicability.
This
study
aimed
develop
a
simple
yet
accurate
AI
model
for
staging
using
only
demographic
biochemical
markers.
retrospective
analyzed
biopsy-proven
data
from
463
MASLD
patients.
Patients
were
randomly
assigned
training
(N
=
370,
80%)
test
93,
20%)
cohorts.
The
incorporated
age,
sex,
BMI,
diabetes,
hypertension,
hyperlipidemia,
blood
markers
(AST,
ALT,
γ-GTP,
HbA1c,
glucose,
triglycerides,
cholesterol).
Support
Vector
Machine
demonstrated
high
diagnostic
performance,
with
an
area
under
the
curve
(AUC)
of
0.886
detecting
significant
(≥
F2).
AUCs
advanced
F3)
cirrhosis
(F4)
0.882
0.916,
respectively.
Compared
FIB-4,
APRI,
FAST
score
(0.80-0.96),
SVM
achieved
comparable
accuracy
eliminating
need
count
or
elastography.
accurately
assesses
patients
without
requiring
Its
simplicity,
cost-effectiveness,
strong
performance
make
it
well-suited
screenings
clinical
use.
World Journal of Hepatology,
Journal Year:
2025,
Volume and Issue:
17(5)
Published: May 27, 2025
BACKGROUND
The
Mac-2
binding
protein
glycosylated
isomer
(M2BPGi)
is
a
serum
marker
for
fibrosis
that
correlates
with
the
stages
in
various
liver
diseases.
AIM
To
examine
M2BPGi’s
threshold
staging
patients
chronic
hepatitis
B
(CHB),
and
its
changes
during
treatment.
METHODS
This
was
prospective,
longitudinal
study.
A
total
of
348
eligible
were
recruited
from
Hepatology
Department,
Medic
Medical
Center
between
March
2020
December
2023.
Liver
enzyme
tests,
platelet
counts,
M2BPGi
levels,
FibroScan
conducted
at
baseline
3-month
intervals
until
six
months
post-treatment.
Correlation
plots
M2BPGi,
FibroScan,
other
parameters
generated.
Receiver
operating
characteristic
curves
constructed
to
evaluate
their
performance.
RESULTS
levels
correlated
well
results
increased
as
stage
advanced.
median
different
showed
statistically
significant
differences.
cut-off
values
diagnosing
(F
≥
2),
advanced
(F3),
cirrhosis
(F4)
determined
be
1.08,
1.4,
1.52,
respectively.
In
context
regression
CHB
first
6-month
treatment,
appeared
decrease
before
this
pattern
occurred
results.
CONCLUSION
strongly
FibroScan.
can
used
assess
fibrosis,
serve
tool
monitoring
undergoing
Hepatology Research,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Sept. 10, 2024
Abstract
Aim
Data
on
the
upregulation
of
Mac‐2
binding
protein
(M2BP)
expression
associated
with
fat
accumulation
in
liver
are
limited.
Therefore,
we
aimed
to
assess
relationship
between
hepatic
M2BP
and
changes
microenvironment
due
patients
metabolic
dysfunction
steatotic
disease
(MASLD).
Methods
Liver
specimens
obtained
from
46
MASLD
were
subjected
immunohistochemical
staining
visualize
liver.
The
intensity
hepatocytes
sinusoidal
cells
was
classified
as
high
or
low
grade.
First,
correlation
microenvironmental
caused
by
examined.
Then,
influence
serum
glycosylation
isomer
levels
evaluated.
Results
grade
higher
than
(
p
=
0.015).
their
had
more
severe
lobular
inflammation
those
0.037).
Additionally,
presented
fibrosis
0.018).
correlated
positively
0.023),
whereas
no
observed
0.393).
Conclusions
Fat
leads
that
fibrosis.
Hepatology Research,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 19, 2024
Abstract
Aim
Type
2
diabetes
mellitus
(T2DM)
is
a
well‐known
risk
factor
for
hepatocellular
carcinoma
(HCC).
However,
HCC
often
diagnosed
at
an
advanced
stage
in
patients
with
because
of
the
lack
best
criteria
surveillance
candidates.
The
aim
this
study
was
to
identify
factors
development
nonviral
chronic
liver
disease.
Method
Three
hundred
thirty
T2DM
disease
who
underwent
by
imaging
techniques
between
2009
and
2020
were
enrolled
multicenter
cross‐sectional
retrospective
study.
clinical
laboratory
parameters
without
compared.
Results
Age
≥65
years,
alcohol
intake,
hepatic
steatosis,
triglyceride
level
<111
mg/dL,
Mac2
binding
protein
glycosylation
isomer
(M2BPGi)
≥0.9
cut‐off
index
(COI),
α‐fetoprotein
concentration
≥5
ng/mL,
des‐γ‐carboxy
prothrombin
≥26
mAU/mL
independently
associated
development.
When
stratified
age,
only
intake
(odds
ratio
[OR]
114.19,
p
<
0.001)
aged
<65
medication
(OR
5.72,
=
0.001),
steatosis
4.47,
0.002),
lactate
dehydrogenase
≥198
IU/L
2.751,
0.031),
M2BPGi
≥1.18
COI
9.05,
FIB‐4
≥2.59
3.22,
0.017)
years.
Conclusions
In
addition
age
fibrosis,
younger
DM
older
should
be
considered
imaging.
World Journal of Gastroenterology,
Journal Year:
2024,
Volume and Issue:
30(47), P. 5070 - 5075
Published: Nov. 25, 2024
In
this
article,
we
comment
on
the
article
by
Qu
and
Li,
focusing
specifically
non-invasive
diagnostic
approaches
for
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD).
MASLD
is
most
common
chronic
in
children.
Nearly
half
of
pediatric
cases
progress
to
steatohepatitis
at
diagnosis,
often
with
comorbidities
like
renal
disease,
hypertension,
type
2
diabetes,
mental
health
disorders.
Early
diagnosis
continuous
intervention
are
crucial
managing
"silent
organ"
disease.
Screening
recommended
children
aged
nine
older
obesity.
Liver
biopsy
remains
gold
standard;
however,
due
its
invasiveness,
methods
-
biomarkers,
anthropometric
algorithms,
serum
tests,
imaging
increasingly
vital.
This
editorial
provides
an
overview
current
or
fibrosis.
Molecules,
Journal Year:
2024,
Volume and Issue:
29(23), P. 5640 - 5640
Published: Nov. 28, 2024
Regular
monitoring
of
patients
with
a
history
hepatitis
C
virus
(HCV)
infection
is
critical
for
the
detection
and
management
hepatocellular
carcinoma
(HCC).
Mac-2
binding
protein
glycosylation
isomer
(M2BPGi)
has
been
used
to
monitor
fibrosis
progression
predict
HCC.
However,
HCC
prediction
based
on
M2BPGi
not
optimized.
Here,
we
identified
risk-related
glycan
signatures
M2BP
using
newly
developed
automated
bead
array
multiplexed
lectins.
Among
955
HCV
who
achieved
sustained
virological
response
following
direct-acting
antiviral
treatment,
compared
from
sera
42
diagnosed
during
follow-up
43
without
(control)
by
lectin
microarray.
At
observation
point,
found
significant
differences
in
17
Using
an
12
lectins,
principal
component
analysis
(PCA)
biplot
differentiated
control,
along
PC1
axis,
explaining
75.2%
variance.
Based
PC1,
generated
scoring
formula
HCC-related
signature
(M2BPgs-HCC),
showing
good
diagnostic
performance
(
